Orca Bio Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
336
- Latest Deal Type
-
2ndary - Private
- Investors
-
16
Orca Bio General Information
Description
Developer of cell therapy products designed to replace patients' diseased blood and immune systems with healthy ones. The company specializes in the research and development of novel cell therapies that help transform all aspects of bone marrow transplantation and create a life-saving platform for many diseases, enabling healthcare professionals to efficiently treat their patients.
Contact Information
Website
www.orcabio.comCorporate Office
- 3475 Edison Way
- Suite C
- Menlo Park, CA 94025
- United States
Corporate Office
- 3475 Edison Way
- Suite C
- Menlo Park, CA 94025
- United States
Orca Bio Timeline
Orca Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 01-May-2026 | Completed | Clinical Trials - Phase 3 | |||
| 5. Later Stage VC (Series F) | 09-Jan-2026 | Completed | Clinical Trials - Phase 3 | |||
| 4. Debt - General | 01-Dec-2023 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series D) | 17-Jun-2020 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC (Series C) | 17-May-2016 | $108M | $133M | Completed | Stealth | |
| 1. Early Stage VC (Series B) | 01-Jan-2016 | $25M | $25M | Completed | Stealth |
Orca Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B-1 | 4,208,618 | $0.000100 | 6% | $1.28 | $1.28 | 1x | $1.28 | 12.36% |
| Series B | 4,000,000 | $0.000100 | 6% | $5 | $5 | 1x | $5 | 11.75% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Orca Bio Comparisons
Industry
Financing
Details
Orca Bio Competitors (3)
One of Orca Bio’s 3 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Cellectis | Formerly VC-backed | Paris, France |
Orca Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Orca Bio Patents
Orca Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026193479-A1 | Methods for allogeneic hematopoietic stem cell transplantation | Pending | 14-Mar-2025 | ||
| WO-2026170029-A1 | Methods for allogeneic hematopoietic stem cell transplantation | Pending | 06-Feb-2025 | ||
| AU-2024338158-A1 | Compositions and methods for treating cancer using cell therapies | Pending | 05-Sep-2023 | ||
| EP-4773991-A1 | Compositions and methods for treating cancer using cell therapies | Pending | 05-Sep-2023 | ||
| US-20260199468-A1 | Compositions and methods for treating cancer using cell therapies | Pending | 05-Sep-2023 | A61K40/31 |
Orca Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Orca Bio Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| LH Ventures (China) | PE/Buyout | Minority | ||
| DCVC | Venture Capital | Minority | ||
| Edgewood Ventures | Family Office | Minority | ||
| Illinois Municipal Retirement Fund | Limited Partner | Minority | ||
| Kaiser Foundation Hospitals | Corporation | Minority |
Orca Bio FAQs
-
When was Orca Bio founded?
Orca Bio was founded in 2015.
-
Where is Orca Bio headquartered?
Orca Bio is headquartered in Menlo Park, CA.
-
What is the size of Orca Bio?
Orca Bio has 336 total employees.
-
What industry is Orca Bio in?
Orca Bio’s primary industry is Drug Discovery.
-
Is Orca Bio a private or public company?
Orca Bio is a Private company.
-
What is Orca Bio’s current revenue?
The current revenue for Orca Bio is .
-
How much funding has Orca Bio raised over time?
Orca Bio has raised $625M.
-
Who are Orca Bio’s investors?
LH Ventures (China), DCVC, Edgewood Ventures, Illinois Municipal Retirement Fund, and Kaiser Foundation Hospitals are 5 of 16 investors who have invested in Orca Bio.
-
Who are Orca Bio’s competitors?
Adaptimmune Therapeutics, Allogene Therapeutics, and Cellectis are competitors of Orca Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
